Press Releases Items Per Page 102550 Year None202020192018201720162015201420132012201120102007 09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences 08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update 08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference 07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020 07.07.20 Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer 05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer 05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update 04.30.20 Syndax Announces Pricing of Public Offering of Common Stock 04.30.20 Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020 04.29.20 Syndax Announces Proposed Public Offering of Common Stock 04.27.20 Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
04.30.20 Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020
04.27.20 Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
